Effect of exenatide on gastric emptying and graft survival in islet allograft recipients

E. M L Peixoto, Tatiana Froud, L. S. Gomes, L. Mireles Zavala, A. Corrales, E. Herrada, Camillo Ricordi, Rodolfo Alejandro

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To evaluate the effect of exenatide on gastric emptying and long-term metabolic control. Methods: Ten islet allograft recipients treated with exenatide up to 4 years. Data from a mixed meal test with (MMT+) versus without (MMT-) administration of exenatide before boost ingestion were analyzed at 6, 12, 24, 36, or 48 months after initiation of exenatide treatment. None of the subjects were symptomatic for gastroparesis before or during the study. The c-peptide, acetaminophen absorption and glucose responses to MMT were analyzed by Student t test and analysis of variance. Results: Average exenatide dose was 12.75 ± 9.46 μg/dL. The MMT subjects included two groups those with acetaminophen peak ≤120 minutes ("good gastric emptying; n = 4") versus those with an acetaminophen peak <180 minutes ("delayed gastric emptying"). Among the MMT+, acetaminophen absorption was the same in both groups (P =.27). Up to 48 months exenatide delayed time to peak of glucose, c-peptide, and acetaminophen as well as suppressed the glucagon response to MMT mean peak: 70.89 ± 12.45 versus 43.24 ± 4.67. The mean values of c-peptide and glucose responses to MMT were not significantly different. Conclusions: Long-term exenatide administration up to 4 years was safe in islet transplant recipients, even in the presence of delayed gastric emptying. The effects of exenatide were acute and reversible when the agent was withdrawn. The main difficulty with the use of exenatide in islet transplant subjects is their poor tolerability, although the physiological effects are clearly evident even at low doses. Approximately 63% of total subjects under exenatide treatment discontinued the drug due to nausea and vomiting. The use of new GLP1 analogs with longer half lives and fewer side effects may help to attain higher GLP1 levels, therefore improving islet function and survival.

Original languageEnglish
Pages (from-to)3231-3234
Number of pages4
JournalTransplantation Proceedings
Volume43
Issue number9
DOIs
StatePublished - Nov 1 2011

Fingerprint

Gastric Emptying
Graft Survival
Allografts
Acetaminophen
Glucose
Peptides
exenatide
Gastroparesis
2-methylcyclopentadienyl manganese tricarbonyl
Glucagon
Nausea
Vomiting
Meals
Analysis of Variance
Eating
Students
Transplants
Survival

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Effect of exenatide on gastric emptying and graft survival in islet allograft recipients. / Peixoto, E. M L; Froud, Tatiana; Gomes, L. S.; Zavala, L. Mireles; Corrales, A.; Herrada, E.; Ricordi, Camillo; Alejandro, Rodolfo.

In: Transplantation Proceedings, Vol. 43, No. 9, 01.11.2011, p. 3231-3234.

Research output: Contribution to journalArticle

Peixoto, E. M L ; Froud, Tatiana ; Gomes, L. S. ; Zavala, L. Mireles ; Corrales, A. ; Herrada, E. ; Ricordi, Camillo ; Alejandro, Rodolfo. / Effect of exenatide on gastric emptying and graft survival in islet allograft recipients. In: Transplantation Proceedings. 2011 ; Vol. 43, No. 9. pp. 3231-3234.
@article{6f08b2edc7834d1f8effa5872347efb9,
title = "Effect of exenatide on gastric emptying and graft survival in islet allograft recipients",
abstract = "Objective: To evaluate the effect of exenatide on gastric emptying and long-term metabolic control. Methods: Ten islet allograft recipients treated with exenatide up to 4 years. Data from a mixed meal test with (MMT+) versus without (MMT-) administration of exenatide before boost ingestion were analyzed at 6, 12, 24, 36, or 48 months after initiation of exenatide treatment. None of the subjects were symptomatic for gastroparesis before or during the study. The c-peptide, acetaminophen absorption and glucose responses to MMT were analyzed by Student t test and analysis of variance. Results: Average exenatide dose was 12.75 ± 9.46 μg/dL. The MMT subjects included two groups those with acetaminophen peak ≤120 minutes ({"}good gastric emptying; n = 4{"}) versus those with an acetaminophen peak <180 minutes ({"}delayed gastric emptying{"}). Among the MMT+, acetaminophen absorption was the same in both groups (P =.27). Up to 48 months exenatide delayed time to peak of glucose, c-peptide, and acetaminophen as well as suppressed the glucagon response to MMT mean peak: 70.89 ± 12.45 versus 43.24 ± 4.67. The mean values of c-peptide and glucose responses to MMT were not significantly different. Conclusions: Long-term exenatide administration up to 4 years was safe in islet transplant recipients, even in the presence of delayed gastric emptying. The effects of exenatide were acute and reversible when the agent was withdrawn. The main difficulty with the use of exenatide in islet transplant subjects is their poor tolerability, although the physiological effects are clearly evident even at low doses. Approximately 63{\%} of total subjects under exenatide treatment discontinued the drug due to nausea and vomiting. The use of new GLP1 analogs with longer half lives and fewer side effects may help to attain higher GLP1 levels, therefore improving islet function and survival.",
author = "Peixoto, {E. M L} and Tatiana Froud and Gomes, {L. S.} and Zavala, {L. Mireles} and A. Corrales and E. Herrada and Camillo Ricordi and Rodolfo Alejandro",
year = "2011",
month = "11",
day = "1",
doi = "10.1016/j.transproceed.2011.10.022",
language = "English",
volume = "43",
pages = "3231--3234",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Effect of exenatide on gastric emptying and graft survival in islet allograft recipients

AU - Peixoto, E. M L

AU - Froud, Tatiana

AU - Gomes, L. S.

AU - Zavala, L. Mireles

AU - Corrales, A.

AU - Herrada, E.

AU - Ricordi, Camillo

AU - Alejandro, Rodolfo

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objective: To evaluate the effect of exenatide on gastric emptying and long-term metabolic control. Methods: Ten islet allograft recipients treated with exenatide up to 4 years. Data from a mixed meal test with (MMT+) versus without (MMT-) administration of exenatide before boost ingestion were analyzed at 6, 12, 24, 36, or 48 months after initiation of exenatide treatment. None of the subjects were symptomatic for gastroparesis before or during the study. The c-peptide, acetaminophen absorption and glucose responses to MMT were analyzed by Student t test and analysis of variance. Results: Average exenatide dose was 12.75 ± 9.46 μg/dL. The MMT subjects included two groups those with acetaminophen peak ≤120 minutes ("good gastric emptying; n = 4") versus those with an acetaminophen peak <180 minutes ("delayed gastric emptying"). Among the MMT+, acetaminophen absorption was the same in both groups (P =.27). Up to 48 months exenatide delayed time to peak of glucose, c-peptide, and acetaminophen as well as suppressed the glucagon response to MMT mean peak: 70.89 ± 12.45 versus 43.24 ± 4.67. The mean values of c-peptide and glucose responses to MMT were not significantly different. Conclusions: Long-term exenatide administration up to 4 years was safe in islet transplant recipients, even in the presence of delayed gastric emptying. The effects of exenatide were acute and reversible when the agent was withdrawn. The main difficulty with the use of exenatide in islet transplant subjects is their poor tolerability, although the physiological effects are clearly evident even at low doses. Approximately 63% of total subjects under exenatide treatment discontinued the drug due to nausea and vomiting. The use of new GLP1 analogs with longer half lives and fewer side effects may help to attain higher GLP1 levels, therefore improving islet function and survival.

AB - Objective: To evaluate the effect of exenatide on gastric emptying and long-term metabolic control. Methods: Ten islet allograft recipients treated with exenatide up to 4 years. Data from a mixed meal test with (MMT+) versus without (MMT-) administration of exenatide before boost ingestion were analyzed at 6, 12, 24, 36, or 48 months after initiation of exenatide treatment. None of the subjects were symptomatic for gastroparesis before or during the study. The c-peptide, acetaminophen absorption and glucose responses to MMT were analyzed by Student t test and analysis of variance. Results: Average exenatide dose was 12.75 ± 9.46 μg/dL. The MMT subjects included two groups those with acetaminophen peak ≤120 minutes ("good gastric emptying; n = 4") versus those with an acetaminophen peak <180 minutes ("delayed gastric emptying"). Among the MMT+, acetaminophen absorption was the same in both groups (P =.27). Up to 48 months exenatide delayed time to peak of glucose, c-peptide, and acetaminophen as well as suppressed the glucagon response to MMT mean peak: 70.89 ± 12.45 versus 43.24 ± 4.67. The mean values of c-peptide and glucose responses to MMT were not significantly different. Conclusions: Long-term exenatide administration up to 4 years was safe in islet transplant recipients, even in the presence of delayed gastric emptying. The effects of exenatide were acute and reversible when the agent was withdrawn. The main difficulty with the use of exenatide in islet transplant subjects is their poor tolerability, although the physiological effects are clearly evident even at low doses. Approximately 63% of total subjects under exenatide treatment discontinued the drug due to nausea and vomiting. The use of new GLP1 analogs with longer half lives and fewer side effects may help to attain higher GLP1 levels, therefore improving islet function and survival.

UR - http://www.scopus.com/inward/record.url?scp=81455143467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81455143467&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.10.022

DO - 10.1016/j.transproceed.2011.10.022

M3 - Article

C2 - 22099764

AN - SCOPUS:81455143467

VL - 43

SP - 3231

EP - 3234

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 9

ER -